You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/111485
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIanhez, Mayra-
dc.contributor.authorMiot, Hélio Amante-
dc.contributor.authorFroes Fleury Junior, Luiz Fernando-
dc.contributor.authorBagatin, Edileia-
dc.date.accessioned2014-12-03T13:08:41Z-
dc.date.accessioned2016-10-25T20:08:40Z-
dc.date.available2014-12-03T13:08:41Z-
dc.date.available2016-10-25T20:08:40Z-
dc.date.issued2013-07-01-
dc.identifierhttp://dx.doi.org/10.1590/abd1806-4841.20131803-
dc.identifier.citationAnais Brasileiros De Dermatologia. Rio De Janeiro Rj: Soc Brasileira Dermatologia, v. 88, n. 4, p. 585-593, 2013.-
dc.identifier.issn0365-0596-
dc.identifier.urihttp://hdl.handle.net/11449/111485-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/111485-
dc.description.abstractActinic keratosis is a common cause of dermatological consultations and it presents a strong association with squamous cell carcinoma. Many substances are used for treatment and prevention, such as retinoids. Nevertheless, many studies on retinoids emphasize their application in treating and preventing non melanoma skin cancers. In this article, we reviewed studies about systemic and topical retinoids used with immunocompetent patients and organ transplant recipients with actinic keratosis, as primary or secondary outcomes. The majority of these papers pointed to a reduction in actinic keratosis count after treatment with retinoids. However, studies need to be better-defined in order to address the lack of a standardized dose, the absence of control groups, the low number of patients and short follow-up periods. Blind, randomized and controlled clinical trials with adequate sample sizes, specifically focused on actinic keratosis, are needed to clarify the real benefit of topical and/or oral retinoids. Comparison of efficacy and safety between oral and topical retinoids in the prevention and treatment of non-melanoma skin cancers and actinic keratosis is an essential pre requisite to establish new strategies to control these conditions.en
dc.format.extent585-593-
dc.language.isoeng-
dc.publisherSoc Brasileira Dermatologia-
dc.sourceWeb of Science-
dc.subjectChemopreventionen
dc.subjectIsotretinoinen
dc.subjectKeratosis, Actinicen
dc.subjectRetinoidsen
dc.subjectTretinoinen
dc.titleRetinoids for prevention and treatment of actinic keratosisen
dc.typeoutro-
dc.contributor.institutionUniversidade Federal de Goiás (UFG)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.description.affiliationFed Univ Goias UFGO, Sao Paulo, Brazil-
dc.description.affiliationSao Paulo State Univ Julio de Mesquita Filho UNES, Sao Paulo, Brazil-
dc.description.affiliationFed Univ Sao Paulo EPM UNIFESP, Sao Paulo, Brazil-
dc.description.affiliationUnespSao Paulo State Univ Julio de Mesquita Filho UNES, Sao Paulo, Brazil-
dc.identifier.doi10.1590/abd1806-4841.20131803-
dc.identifier.scieloS0365-05962013000400585-
dc.identifier.wosWOS:000324929100012-
dc.rights.accessRightsAcesso aberto-
dc.identifier.fileS0365-05962013000400585.pdf-
dc.relation.ispartofAnais Brasileiros de Dermatologia-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.